MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose
Jeremy Booth, Vincent Caillet, Adam Briggs, Nicholas Hardcastle, Georgios Angelis, Dasantha Jayamanne, Meegan Shepherd, Alexander Podreka, Kathryn Szymura, Trang Nguyen Doan, Per Poulsen, Ricky O'Brien, Benjamin Harris, Carol Haddad, Thomas Eade, Paul Keall
Radiotherapy and Oncology | ELSEVIER IRELAND LTD | Published : 2021
BACKGROUND AND PURPOSE: The purpose of this work is to present the clinical experience from the first-in-human trial of real-time tumor targeting via MLC tracking for stereotactic ablative body radiotherapy (SABR) of lung lesions. METHODS AND MATERIALS: Seventeen patients with stage 1 non-small cell lung cancer (NSCLC) or lung metastases were included in a study of electromagnetic transponder-guided MLC tracking for SABR (NCT02514512). Patients had electromagnetic transponders inserted near the tumor. An MLC tracking SABR plan was generated with planning target volume (PTV) expanded 5 mm from the end-exhale gross tumor volume (GTV). A clinically approved comparator plan was generated with PT..View full abstract
Awarded by Royal North Shore Hospital
The authors acknowledge Varian Medical Systems and Royal North Shore Hospital No2 Trust for supporting this study.